Life Extension Skin Care Sale

Life Extension Magazine

LE Magazine May 2005
image

The Lifesaving Benefits of Annual Blood Screening

By Penny Baron

Cardio C-Reactive Protein (high sensitivity)

Inflammation is a pathogenic mechanism for development and progression of atherosclerosis and heart disease, as well as other disorders such as arthritis, cancer, and autoimmune conditions. C-reactive protein (CRP) is a very sensitive marker of systemic inflammation, and has emerged as a powerful predictor of coronary heart disease and other diseases of the cardiovascular system.23

Elevated levels of CRP have also been associated with the risk for developing type II diabetes,24 loss of cognitive ability in seemingly healthy people,25 and major depression in men.26

A study published in the New England Journal of Medicine in January 2005 found that among patients who were given statin drugs to lower cholesterol, those who achieved lower CRP levels had better clinical outcomes than those with higher CRP levels. The investigators concluded, “strategies to lower cardiovascular risk with statins should include monitoring CRP as well as cholesterol.”27

The highly sensitive cardio CRP test measures C-reactive protein in the blood at very early stages of vascular disease, allowing for appropriate intervention with diet, supplements, or anti-inflammatory therapy. The cardio CRP test detects much smaller levels of inflammation than the regular CRP test, so is therefore able to identify at-risk patients earlier, even among apparently healthy persons.

A review of epidemiological data found that high-sensitivity cardio CRP was able to predict risk of incident myocardial infarction, stroke, peripheral arterial disease, and sudden cardiac death among healthy individuals with no history of cardiovascular disease, and predict recurrent events and death in patients with acute or stable coronary syndromes. This inflammatory marker provided prognostic information that was independent of other measures of risk such as cholesterol level, metabolic syndrome, and high blood pressure. Greater levels of cardio CRP are associated with higher cardiovascular risk.28 High-sensitivity CRP testing also reveals systemic inflammation that is associated with disease activity in patients with rheumatoid arthritis.29

Prostate-Specific Antigen (Male Panel Only)

Prostate-specific antigen (PSA) is a protein manufactured by the cells of the prostate gland in men. Elevated PSA levels can suggest benign prostatic enlargement, prostate inflammation, or prostate cancer. Measurement of PSA levels is thus a screening tool. PSA may also be used to monitor progression of prostate disease and response to treatment.

The PSA test has been widely used since the early 1990s. During that time, the prostate cancer death rate has dropped. The American Cancer Society recommends annual PSA testing beginning at age 50. Men who are at high risk should begin PSA testing at age 40-45. PSA levels go up with age, even in the absence of prostate abnormalities.30

PSA velocity is the change in PSA values over time. It is determined by monitoring PSA values over the course of one or more years. PSA values that increase dramatically over time suggest that cancer may be present and a biopsy should be considered.31

A recent study demonstrated that PSA levels tend to be lower in obese men than in men of normal weight. As a result, physicians may not suspect prostate enlargement or cancer in heavier men, and these conditions may go undetected. Therefore, physicians must be particularly diligent when screening heavier men for prostate conditions. A digital rectal exam may be used as an additional screening tool along with PSA testing.32

Conclusion

The Male and Female Panel discussed above can be your best defense against a range of degenerative diseases including cardiovascular disease, diabetes, cancer, stroke, immune disorders, blood abnormalities and inflammation. Armed with these annual lab findings, you can take timely and critical steps to prevent many of the diseases associated with aging.

View Male and Female Panel Charts
(You will need Adobe® Reader® installed on your computer to view this file.)

Penny Baron is a retrovirologist at a New York City hospital. She holds masters degrees in microbiology and clinical nutrition.

References

1. Heller T, Hoschstetter V, Basler M, Borck V. Vitamin B6-sensitive hereditary sideroblastic anemia. Dtsch Med Wochenschr. 2004 Jan 23;129(4):141-4.

2. Fishman SM, Christian P, West KP. The role of vitamins in the prevention and control of anemia. Public Health Nutr. 2000 Jun;3(2):125-50.

3. Beers MH, Berkow R, eds. The Merck Manual of Diagnosis and Therapy. 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999:931.

4. Haq IU, Ramsay LE, Jackson PR, Wallis EJ. Prediction of coronary risk for primary prevention of coronary heart disease: a comparison of methods. QJM. 1999 Jul;92(7):379-85.

5. Wilson PW. Assessing coronary heart disease risk with traditional and novel risk factors. Clin Cardiol. 2004 Jun;27(6 Suppl 3):III7-11.

6. Moffat SD, Zonderman AB, Metter EJ, et al. Free testosterone and risk for Alzheimer disease in older men. Neurology. 2004 Jan 27;62(2):188-93.

7. Leifke E, Gorenoi V, Wichers C, Von Zur Muhlen A, Von Buren E, Brabant G. Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men: cross-sectional data from a healthy male cohort. Clin Endocrinol (Oxf). 2000 Dec;53(6):689-95.

8. Barrett-Connor E, von Muhlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab. 1999 Feb;84(2):573-7.

9. Dhindsa S, Prabhakar S, Sethi M, et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2004 Nov;89(11):5462-8.

10. Dunajska K, Milewicz A, Szymczak J, et al. Evaluation of sex hormone levels and some metabolic factors in men with coronary atherosclerosis. Aging Male. 2004 Sep;7(3):197-204.

11. Tan RS, Pu SJ. A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer’s disease. Aging Male. 2003 Mar;6(1):13-7.

12. Lovejoy JC, Bray GA, Bourgeois MO, et al. Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women—a clinical research center study. J Clin Endocrinol Metab. 1996 Jun;81(6):2198-203.

13. Leowattana W. DHEA(S): the fountain of youth. J Med Assoc Thai. 2001 Oct;84 Suppl 2S605-12.

14. Key TJ. Serum oestradiol and breast cancer risk. Endocr Relat Cancer. 1999 Jun;6(2):175-80.

15. Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer. 2004 Jan 20;108(3):425-32.

16. Goderie-Plomp HW, van der KM, de Ronde W, et al. Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: the Rotterdam Study. J Clin Endocrinol Metab. 2004 Jul;89(7):3261-9.

17. Carlsen CG, Soerensen TH, Eriksen EF. Prevalence of low serum estradiol levels in male osteoporosis. Osteoporos Int. 2000;11(8):697-701.

18. Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM. Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry. 2003 Jun;60(6):618-26.

19. Teunissen CE, Blom AH, Van Boxtel MP, et al. Homocysteine: a marker for cognitive performance? A longitudinal follow-up study. J Nutr Health Aging. 2003;7(3):153-9.

20. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992 Aug 19;268(7):877-81.

21. an Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med. 2004 May 13;350(20):2033-41.

22. McLean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med. 2004 May 13;350(20):2042-9.

23. Koenig W, Sund M, Frohlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999 Jan 19;99(2):237-42.

24. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001 Jul 18;286(3):327-34.

25. Teunissen CE, Van Boxtel MP, Bosma H, et al. Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol. 2003 Jan;134(1-2):142-50.

26. Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2004 May 10;164(9):1010-4.

27. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005 Jan 6;352(1):20-8.

28. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol. 2004 Aug;29(8):439-93.

29. Dessein PH, Joffe BI, Stanwix AE. High sensitivity C-reactive protein as a disease activity marker in rheumatoid arthritis. J Rheumatol. 2004 Jun;31(6):1095-7.

30. Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_4_3X_Can_prostate_cancer_be_found_early_36.asp: Accessed February 28, 2005.

31. Berger AP, Deibl M, Steiner H, et al. Longitudinal PSA changes in men with and without prostate cancer: Assessment of prostate cancer risk. Prostate. 2005 Feb 14.

32. Baillargeon J, Pollock BH, Kristal AR, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer. 2005 Mar 1;103(5):1092:5.